Immunotherapy with NK cells
Phase 1
- Conditions
- Clinical study to investigate safety and efficacy on NK cells to health and cancer
- Registration Number
- JPRN-UMIN000002134
- Lead Sponsor
- Kuramae clinic
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Not provided
Exclusion Criteria
1.Uncontrollable infection 2.Serious cardiac disease 3.Active autoimmune disease 4.Pulmonary fibrosis or interstitial pneumonia, or their history, or predisposition to them 5.Serious drug allergy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety
- Secondary Outcome Measures
Name Time Method Antitumor effect Progression-free survival Overall survival QOL Immunological responses